Grace Therapeutics (GRCE) 10% Owner Opaleye Management Buys Shares

What Happened

• Opaleye Management, Inc. — reported as the investment manager for Opaleye, L.P. (a 10% owner) — purchased 11,608 shares of Grace Therapeutics (GRCE) on 2026-08-14. The filing reports a weighted-average price of $2.09 per share for a reported total of $24,206. This was an acquisition (purchase), which is generally considered a more informative/bullish signal than a sale, though institutional buys can reflect portfolio adjustments as well.

Key Details

• Transaction date: 2026-08-14 (reported on Form 4 filed 2026-08-19).
• Transaction type: Purchase (code P); described as open market or private purchase.
• Price details: Weighted average price $2.09; individual trades ranged from $2.05 to $2.09 (filing commits to provide breakdown on request).
• Shares acquired: 11,608; reported total value: $24,206.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Filing timeliness: Form 4 was filed five days after the trade date; this appears to be outside the typical two-business-day reporting window for Section 16 filers.
• Notable footnotes: F1 clarifies the securities are owned directly by Opaleye, L.P., for which Opaleye Management acts as investment manager; F2 explains the weighted-average price and price range; F3 disclaims beneficial ownership by Opaleye Management except to the extent of its pecuniary interest.

Context

• This is an institutional purchase by a 10% owner (Opaleye/Opaleye, L.P.), not an individual executive. Institutional buys can signal conviction but may also reflect portfolio strategy or fund flows. The filing is factual and does not explain motivation.